<DOC>
	<DOCNO>NCT01795027</DOCNO>
	<brief_summary>Background : It show TS-1 adjuvant chemotherapy D2 resection patient gastric cancer improve DFS OS one Japanese Trial . And TS-1 become one standard therapies patient . But still unknown whether would improve OS DFS single TS-1 combine oxaliplatin . This trial design investigate efficacy safety TS-1 plus oxaliplatin versus TS-1 single adjuvant chemotherapy D2 resection patient gastric cancer . Patients method : In study , patient histologically confirm gastric cancer receive D2 resection stag II III , age 18 70 year Eastern Cooperative Oncology Group performance status â‰¤2 adequate organ function , randomize 1:1 oxaliplatin 100mg/m2 day 1 TS-1 40~60mg twice everyday 14 day 21-days cycle total 6 cycle follow TS-1 single dose frequency end 1st year postoperatively ( SOX ) , TS-1 single 40~60mg twice everyday 14 day 21-days cycle end 1st year postoperatively ( TS-1 ) . The primary end point overall survival ( OS ) , secondary end point disease free survival ( DFS ) safety . Final study analysis conduct end 5th year last patient 's enrollment .</brief_summary>
	<brief_title>Compare S-1 Plus Oxaliplatin S-1 Adjuvant Chemotherapy After D2 Resection Patients With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>inform consensus patient able receive oral administration 18 70 year old proven primary adenocarcinoma gastric cancer stag II III pathological evidence without chemotherapy and/or radiation disease normal function organ include heart , liver , kidney Eastern Cooperative Oncology Group performance status:0~2 history malignancy allergic reaction S1 oxaliplatin enrol clinical trial abnormal GI tract function dysfunction organ female pregnancy lactation , refuse receive Contraception measure chemotherapy situation judge adaptive study investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>D2 resection</keyword>
	<keyword>S-1</keyword>
</DOC>